642091-49-4

Basic information

• Product Name: 2,5-dibromobenzyl chloride
• Synonyms: 2,5-dibromobenzyl chloride
• CAS NO: 642091-49-4
• Molecular Weight: 284.378
• Mol File: 642091-49-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,5-dibromobenzyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-dibromobenzyl chloride(642091-49-4)
• EPA Substance Registry System: 2,5-dibromobenzyl chloride(642091-49-4)

Safety Data

• Hazardous Substances Data: 642091-49-4(Hazardous Substances Data)

Usage

Physical state

White to light brown solid

Reactivity

Highly reactive

Common uses

Building block in organic synthesis, intermediate in pharmaceutical production, reagent in preparation of other organic compounds

Versatility

Useful component in a wide range of chemical processes and applications

Research and development uses

Synthesis of various pharmaceuticals and agrochemicals as a starting material

Upstream product

• 50-00-0 formaldehyd 
• 106-37-6 1.4-dibromobenzene 
• 610-71-9 2,5-dibromobenzoic acid 
• 147034-01-3 (2,5-dibromophenyl)methanol 

Downstream Products

• 74553-29-0 2,5-dibromobenzaldehyde 
• 74533-21-4 2-(2,5-dibromophenyl)acetonitrile 
• 203314-28-7 2-(2,5-dibromophenyl)-acetic acid 
• 203314-51-6 (2,5-dibromo-phenyl)-acetyl chloride 

Relevant articles and documents

Synthetic method for 2,5-dibromophenylacetic acid

The invention discloses a synthetic method for an intermediate 2,5-dibromophenylacetic acid of an anti-HCV drug. According to the invention, dibromobenzene is used as a raw material and is subjected to chloromethylation, cyanidation and hydrolysis success

Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity

The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38α, and p38δ and showed little inhibitory activity against a panel of 74 kinases.